Abstract
NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.
MeSH terms
-
Animals
-
Antineoplastic Agents / metabolism
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Humans
-
Liposomes / metabolism*
-
Mice
-
Neoplasms / therapy*
-
Oligodeoxyribonucleotides / adverse effects
-
Oligodeoxyribonucleotides / metabolism
-
Oligodeoxyribonucleotides / pharmacokinetics
-
Oligodeoxyribonucleotides / therapeutic use*
-
Oligodeoxyribonucleotides, Antisense / adverse effects
-
Oligodeoxyribonucleotides, Antisense / genetics
-
Oligodeoxyribonucleotides, Antisense / metabolism
-
Oligodeoxyribonucleotides, Antisense / therapeutic use*
-
Proto-Oncogene Proteins c-raf / genetics
-
Proto-Oncogene Proteins c-raf / metabolism
-
Proto-Oncogene Proteins c-raf / therapeutic use*
Substances
-
Antineoplastic Agents
-
LErafAON
-
Liposomes
-
Oligodeoxyribonucleotides
-
Oligodeoxyribonucleotides, Antisense
-
Proto-Oncogene Proteins c-raf